Lumbar Degenerative Disc Disease (LDDD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Lumbar Degenerative Disc Disease (LDDD) Market Outlook

Thelansis’s “Lumbar Degenerative Disc Disease (LDDD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Lumbar Degenerative Disc Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Lumbar Degenerative Disc Disease (LDDD) Overview

The Lumbar Degenerative Disc are pads made of fibrocartilage-based structures that lie between each vertebral body of the spine and offer support, flexibility, and a small amount of load-sharing. Growing patient age is closely associated with disc deterioration. Women with disc degeneration are likely to be more susceptible to the effects, even though it is believed that men probably start this degeneration almost ten years sooner than women. Non-surgical treatments consist of cognitive therapy, epidural injections, non-steroidal anti-inflammatory drugs (NSAIDs), lifestyle adjustment, and modifying activities that can worsen the pain. A lot of patients don't improve with conservative care. The patient is left with three options if the conservative approach fails: more suffering, total avoidance of pain-inducing activities, or surgery. Once more, patients with neurologic impairments, degenerative spondylolisthesis, or pain that interferes with everyday functioning should be considered for surgical alternatives for disc herniations and degenerative spinal stenosis.

• An estimated 266 million people are projected to have adult DSD annually. Europe and North America are expected to have the highest annual incidences of DSD and back pain per capita (5668 and 4501 per 100,000 individuals, respectively.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: